我要投票 承慶堂在医疗器械行业中的票数:70
· 外 推 电 报 ·
2025-01-18 20:31:21 星期六

【承慶堂是哪个国家的品牌?】

承慶堂是什么牌子?「承慶堂」是 安徽承庆堂国药股份有限公司 旗下著名品牌。该品牌发源于安徽省亳州市,由创始人李整风在2012-01-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

安徽承庆堂国药股份有限公司(原亳州正丰医药有限责任公司)是于2001年投资建设的集医疗器械生产与销售一体化公司,是一家集医疗器械的技术研发、技术咨询为产业核心,采用国际OEM模式,以掌控知识产权为入手、以医药科研为主的企业,主打“承庆堂”骨病系列外用贴剂产品,以疗效显著、品质稳定深得广大骨科医院及消费者的认可和好评。公司在医药行业经过短短几年的发展历程,依靠自身产品的绝对疗效已形成了骨病系列外用贴剂的知名品牌。“品质决定品牌”,创造骨病系列外用贴剂的医药品牌是正丰医药人孜孜不倦和执着追求的目标。

公司拥有一支团结、创新、奋进的技术研发队伍,在公司全体员工的共同努力下,企业坚持走专业化道路,形成了“材料来源基地化,检测手段科学化,制作工艺规范化,贴剂质量标准化,设计包装规格化”的“五化”管理模式,产品“选料上乘,工艺考究,疗效显著”。提升了“承庆堂”品牌的知名度和美誉度。始终坚持靠诚信打造自身品牌、靠质量占领市场先机、靠服务赢得行业机遇、靠管理推动企业发展的理念,在严峻的医药行业形势下,注重发挥自身优势,做大做强主营业务,我们坚信“一生只做一件事”,在同行业内取得了骄人的业绩,公司在发展过程中,得到了各级领导和相关职能管理部门的正确指引和极大的关怀,在广大医药流通企业和商业客户的支持下,在全国药业行业中,凭借自身实力和产品品质,铸就了企业在医药行业及广大骨科医院的巩固地位。目前,公司已与国内多家骨科医院和众多客户建立了紧密、稳固的合作关系,形成了强大的销售网络和品牌优势。公司也一直专注于现代企业制度的建设,目前已经在企业的产权结构、运营模式、管理制度、业务流程上达到了一定水平,并形成了自己的特色。

公司自2007年就尝试运作终端销售模式,即在有条件的骨科医院设立精品药房,截至目前已在国内多家骨科医院建立了上百家精品药房,此模式的成功运作,有利于实现名企、名院、名医、名品的优化组合,扩大医疗机构的服务范围,为患者提供疗效显著、价格合理的诚信医疗服务。我们诚邀各大骨科医院垂询来访,共筑合作平台,实现医药携手共赢发展。

在如今医药行业新的竞争和挑战中,我们将拥有更加广阔的医药市场。“海内存知己,天涯若比邻”,公司愿与全国各大骨科医院、连锁药房及各界的朋友真诚合作、共创辉煌!



英文翻译:Anhui chengqingtang State Pharmaceutical Co., Ltd. (formerly Bozhou Zhengfeng Pharmaceutical Co., Ltd.) is an integrated production and sales company of medical devices invested and constructed in 2001. It is an enterprise that focuses on technical research and development and technical consultation of medical devices, adopts the international OEM mode, controls intellectual property rights and focuses on medical research, and focuses on "chengqingtang" osteopathy A series of external patch products, with remarkable curative effect and stable quality, have won the recognition and praise of orthopedic hospitals and consumers. After just a few years of development in the pharmaceutical industry, relying on the absolute efficacy of its own products, the company has formed a well-known brand of bone disease series external patches. "Quality determines the brand" and creating a brand of external use of orthopedic patches is the goal of Zhengfeng pharmaceutical people. The company has a united, innovative and progressive technology research and development team. With the joint efforts of all employees, the company adheres to the path of specialization, forming a "five chemical" management mode of "base of material sources, scientific detection means, standardized production process, standardized paste quality, standardized design and packaging". The product "selects the best materials, exquisite technology, and curative effect" Remarkable. It has improved the popularity and reputation of chengqingtang brand. We always adhere to the concept of building our own brand by integrity, seizing the market opportunity by quality, winning industry opportunities by service, and promoting enterprise development by management. Under the severe situation of the pharmaceutical industry, we pay attention to giving full play to our own advantages and making our main business bigger and stronger. We firmly believe that "only one thing in life" has made remarkable achievements in the same industry. In the process of development, the company has obtained With the correct guidance and great care of leaders at all levels and relevant functional management departments, supported by the majority of pharmaceutical circulation enterprises and commercial customers, and with its own strength and product quality in the national pharmaceutical industry, the company has established a firm position in the pharmaceutical industry and the majority of orthopedic hospitals. At present, the company has established close and stable cooperative relations with many orthopedic hospitals and customers in China, forming a strong sales network and brand advantages. The company has also been focusing on the construction of modern enterprise system. At present, it has reached a certain level in the property right structure, operation mode, management system and business process of the enterprise, and has formed its own characteristics. Since 2007, the company has tried to operate terminal sales mode, that is, to set up boutique pharmacies in conditional orthopedic hospitals. Up to now, hundreds of boutique pharmacies have been set up in many orthopedic hospitals in China. The successful operation of this mode is conducive to the realization of the optimized combination of famous enterprises, famous hospitals, famous doctors and famous products, the expansion of the service scope of medical institutions, and the provision of significant curative effect and reasonable price for patients The integrity of medical services. We sincerely invite all orthopedic hospitals to visit us and build a cooperation platform to achieve win-win development of medicine. In today's new competition and challenges in the pharmaceutical industry, we will have a broader pharmaceutical market. "Friends in the sea, the end of the world is like a neighbor", the company is willing to sincerely cooperate with all major orthopedic hospitals, chain pharmacies and friends from all walks of life to create brilliant!

本文链接: https://www.waitui.com/brand/8a4ae9536.html 联系电话:05585366999

千城特选小程序码

7×24h 快讯

姚伟雄先生将不再担任安踏集团时尚运动品牌群 CEO 职务,江艳女士将接任时尚运动品牌群 CEO

36氪获悉,因已届退休年龄,姚伟雄先生将不再担任安踏集团时尚运动品牌群 CEO 职务,未来他将继续担任集团副总裁,负责集团时尚产业项目的日常管理与运营。自 2010 年起,姚伟雄先生一直负责 FILA品牌大中华地区的业务,带领团队将 FILA 打造成中国时尚运动赛道的标杆品牌,跻身中国前五大运动品牌之列。集团高度肯定姚伟雄先生为公司和行业所做出的杰出贡献,并祝愿他在新的岗位继续发挥更多的才能。 江艳女士将接任时尚运动品牌群 CEO,全面负责时尚运动品牌群的经营管理,继续推动 FILA 夯实“高端时尚运动品牌“的心智定位,实现品牌驱动的业务增长。江艳女士是集团长期培养的年轻梯队干部,拥有丰富的品牌管理经验,曾先后操盘 ANTA KIDS FILA FUSION 的品牌管理工作,实现了两个品牌在细分市场的领先心智。她将领导 FILA 进一步拓展在年轻人群中的影响力,为消费者创造更多的价值。

32分钟前

国新创投基金启航 首期规模100亿元

中国国新联合部分中央企业、地方国资1月18日在京共同举行国新创投基金合作签约仪式。国新创投基金出资合作单位有中国五矿、中国钢研、中国建材、中国有研、中国电气装备、杭州资本、兴湘集团等,首期规模100亿元,存续期15年,同时将启动杭州、湖南、西安等一批子基金,通过母子基金放大方式,围绕“国家所需、创新所要、基金所能”,坚持投早、投小、投长期、投硬科技,为科技强国建设和新质生产力培育贡献力量。(财联社)

32分钟前

新凤鸣入选首批国家工信部“卓越级智能工厂”

近日,新凤鸣集团“化纤全产业链协同智能工厂”入选国家“卓越级智能工厂(第一批)项目名单(共235家)”,是浙江省上榜的13家企业之一,也是化纤行业唯一上榜企业。(证券时报)

32分钟前

先锋集团将支付1.06亿美元以和解美国SEC指控

美国证券交易委员会(SEC)当地时间1月17日在一份新闻稿中指出,先锋集团(The Vanguard Group, Inc.)将支付1.0641亿美元,以和解有关其对资本利得分配和税收影响的误导性陈述的指控,这些误导性陈述影响了在应纳税账户中持有先锋投资者目标退休基金(Investor TRFs)的零售投资者。和解金额将分配给受影响的投资者。(财联社)

32分钟前

今年首家!千亿公募换帅

2025年开年,公募基金行业迎来今年首次基金公司换帅。1月18日,兴银基金发布基金行业高级管理人员变更公告,公告显示,易勇新任兴银基金总经理,同时,董事长吴若曼不再代为履行总经理职务。 Wind数据显示,截至2024年9月30日,兴银基金旗下公募产品数量54只,公募管理规模为1067.32亿元。根据银河证券数据显示,近二年固收排名40/129,近三年排名32/119,近五年排名9/93,在权益方面,兴银基金近两年排名进入前10%(12/124)。(券商中国)

32分钟前

本页详细列出关于伟思VISHEE的品牌信息,含品牌所属公司介绍,伟思VISHEE所处行业的品牌地位及优势。
咨询